A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Public ClinicalTrials.gov record NCT06797869. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Study identification
- NCT ID
- NCT06797869
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 142 participants
Conditions and interventions
Interventions
- CagriSema (Cagrilintide B and Semaglutide I) Drug
- Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2025 (Actual)
- Primary completion
- Jun 26, 2026 (Actual)
- Completion
- Aug 5, 2026 (Actual)
- Last update posted
- Sep 10, 2026
2025 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| eStudySite | La Mesa | California | 91942 | — |
| Linda Vista Health Care Ctr | San Diego | California | 92111 | — |
| My Preferred Research | Miami | Florida | 33155 | — |
| New Horizon Research Center | Miami | Florida | 33165 | — |
| Renstar Medical Research | Ocala | Florida | 34470 | — |
| Renstar Medical Research | Ocala | Florida | 34471 | — |
| Foot & Ankle Center of Illinois | Springfield | Illinois | 62704 | — |
| Velocity Clinical Research Rockville | Rockville | Maryland | 20854 | — |
| Amicis Centers of Clinical Research | St Louis | Missouri | 63128 | — |
| DM Clinical | Albuquerque | New Mexico | 87106 | — |
| Southgate Medical Group, LLP | West Seneca | New York | 14224 | — |
| Piedmont Healthcare/Research | Statesville | North Carolina | 28625 | — |
| Lillestol Research LLC | Fargo | North Dakota | 58104 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Clinical Res Collaborative | Cumberland | Rhode Island | 02864 | — |
| DM Clinical | Houston | Texas | 77081 | — |
| Radiance Clinical Research | Lampasas | Texas | 76550 | — |
| DM Clinical Research | San Antonio | Texas | 78207 | — |
| DM Clinical | San Antonio | Texas | 78207 | — |
| Velocity Clinical Research Portsmouth | Suffolk | Virginia | 23435 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06797869, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06797869 live on ClinicalTrials.gov.